Navigation Links
FDA-approved drug restores hair in patients with Alopecia Areata
Date:8/17/2014

l now, only two small clinical trials evaluating targeted therapies in alopecia areata have been performed, largely because of the lack of mechanistic insight into it."

"The timeline of moving from genetic findings to positive results in a clinical trial in only four years is astoundingly fast and speaks to this team's ability to perform translational science of the highest caliber," said David Bickers, MD, the Carl Truman Nelson Professor of Dermatology and chair of the Department of Dermatology at CUMC and dermatologist-in-chief at NewYork-Presbyterian/Columbia. A practicing dermatologist who cares for many patients with alopecia areata himself, Dr. Bickers said, "There are few tools in the arsenal for the treatment of alopecia areata that have any demonstrated efficacy. This is a major step forward in improving the standard of care for patients suffering from this devastating disease."

But as Dr. Christiano knows firsthand from her own personal experience with the disease, alopecia areata is too often dismissed as simply an appearance-altering disease. "Nothing could be further from the truth," she said. "Patients with alopecia areata are suffering profoundly, and these findings mark a significant step forward for them. The team is fully committed to advancing new therapies for patients with a vast unmet need."


'/>"/>
Contact: Karin Eskenazi
ket2116@cumc.columbia.edu
212-342-0508
Columbia University Medical Center
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. Drug design success propels efforts to fight HIV with a combination of 2 FDA-approved drugs
2. Promising compound restores memory loss and reverses symptoms of Alzheimers
3. The nose knows: Gene therapy restores sense of smell in mice
4. Gene network restores CF protein function
5. NSAIDs benefit overweight breast cancer patients, study finds
6. Many older emergency department patients are malnourished
7. Discovery of new form of dystrophin protein could lead to therapy for some DMD patients
8. Patients with autism spectrum disorder are not sensitive to being imitated
9. Patients with hypoventilation may need supplemental oxygen on-board flights
10. Acupuncture at Waiguan improves activation of functional brain areas of stroke patients
11. Test increases odds of correct surgery for thyroid cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA-approved drug restores hair in patients with Alopecia Areata
(Date:8/20/2015)... CLARA, Calif. , Aug. 20, 2015 /PRNewswire/ ... company focused on improving the user experience and ... and vision technologies, today announced that its ... voice biometric authentication software to be FIDO ... tested TrulySecure for compliance with the FIDO UAF ...
(Date:8/17/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... 2015. The new marketing campaign is being spearheaded by ... Group ( http://amplitudemarketing.com/ ) and TPMG ( http://tmpg.com/ ). ... retail driven marketing and brand awareness and has a ...
(Date:8/11/2015)... , August 11, 2015 Today, ZUK announced ... received as well as expected revenues in 2015 that relate to ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ... a prominent smartphone manufacturer in ... selected FPC1 155 for ...
Breaking Biology News(10 mins):TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2
... The 2008 recipients of The Dr. Paul Janssen Award ... and Emeritus Professor Sir Ravinder Maini, FRCP, FMedSci, FRS ... are being honored during a scientific symposium today and ... Janssen Research Center in Beerse, Belgium tomorrow. Feldmann ...
... In the world of Down syndrome, ,Mr. C, is a rarity. ... 16 years, at seventy, ,Mr. C, has well surpassed the average ... late fifties, but in the teens when ,Mr. C, was born. ... which is almost a given for people with typical Down syndrome ...
... Authentication Technology with, Single-Sign On Solutions Cost-Effectively Bolsters Security ... ... Calif., Sept. 9 Fujitsu Computer Products of,America, Inc., ... drives, peripherals and biometric security solutions, today,announced the availability ...
Cached Biology News:Johnson & Johnson honors 2008 recipients of the Dr. Paul Janssen Award for Biomedical Research 270 years old and going strong with Down syndrome and no dementia 2Fujitsu Announces PalmSecure(TM) LOGONDIRECTOR 2Fujitsu Announces PalmSecure(TM) LOGONDIRECTOR 3Fujitsu Announces PalmSecure(TM) LOGONDIRECTOR 4
(Date:8/26/2015)... 2015 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced that the Company has been informed that Magnum ... owned by Mr. Yuen Kam, chairman of the board ... shares (the "Shares") of  Excellent China Healthcare Investment Limited ...
(Date:8/26/2015)... ... August 26, 2015 , ... PRC Clinical, a Clinical Trial ... with local sponsors in southern California. The Clinical Trial Management Expert CRO seeks to ... regulatory pathways., , Stem Cell Meeting on the Mesa ...
(Date:8/25/2015)... Washington, USA, and CARDIFF, UK (PRWEB) , ... ... ... more quickly and accurately determining whether breast tissue lesions are cancerous is described ... published by SPIE, the international society for optics and photonics. , In “ ...
(Date:8/25/2015)... (PRWEB) , ... August 25, 2015 , ... One of ... -based Resilinc Corp., Bindiya Vakil, has been on a mission for the ... impact on global supply chain operations - from the two massive explosions that occurred ...
Breaking Biology Technology:China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 2New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 3New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 4Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 2Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 3Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 4
... - Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ.NEPT - ... the fiscal 2009 third quarter and nine-month period ended ... for its fiscal year 2009 now ending on February, ... period ended February 28, 2009 in the range of ...
... regular improvements in information technology, says Slava Rotkin, but ... Take the laptop, for example. Its components, especially its ... while the instrument,s power and capacity increase. But heat ... melt and the laptop hardware to fail. , Indeed, ...
... Approval for SIMPONI , ... Ortho Biotech Inc. and Schering-Plough Corporation (NYSE: ... granted approval of SIMPONI (TM) (golimumab),as a once-monthly, ... active rheumatoid arthritis (RA), active psoriatic arthritis (PsA),and ...
Cached Biology Technology:Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 2Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 3Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 4Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 5New 'near-field' radiation therapy promises relief for overheating laptops 2New 'near-field' radiation therapy promises relief for overheating laptops 3Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 2Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 3Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 4Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 5Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 6Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 7Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 8
Mouse monoclonal [050-04] to C2 ( Abpromise for all tested applications). entrezGeneID: 717 SwissProtID: P06681...
Rabbit polyclonal to Bag5 ( Abpromise for all tested applications). entrezGeneID: 9529 SwissProtID: Q9UL15...
Rabbit polyclonal to Tryptophanyl tRNA synthetase ( Abpromise for all tested applications). Antigen: Recombinant full length protein (Human): Tryptophanyl tRNA synthetase Entrez Gene ID: 745...
WTAP Antibody...
Biology Products: